If it were only that simple

European Heart Journal

Volumn 37, Issue 20, 2016, Pages 1603-1605

  Reiffel, James A ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BIOLOGICAL MARKER;

ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; BLEEDING; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMORBIDITY; HUMAN; IMPLANTED HEART PACEMAKER; META ANALYSIS (TOPIC); MORBIDITY; PAROXYSMAL ATRIAL FIBRILLATION; PERMANENT ATRIAL FIBRILLATION; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW (TOPIC); THROMBOEMBOLISM;

EID: 84975706417     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehw014     Document Type: Review

References (11)

1. Ganesan AN, Chew D, Hartshorne T, Selvanayagam J, Aylward P, Sanders P, McGavigan A. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: A systematic review and meta-analysis. Eur Heart J 2016;37:1591-1602.
2. Vanassche T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M, Avezum A, Diaz R, Hohnloser SH, Lewis BS, Shestakovska O, Wang J, Connolly SJ. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirintreated patients in ACTIVE-A and AVERROES. Eur Heart J 2015;36:281-287.
3. Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Hankey GJ, Becker RC, Singer DE, Halperin JL, Hacke W, Nessel CC, Berkowitz SD, MahaffeyKW, Fox KA, Califf RM, Piccini JP, ROCKET-AF Steering Committee and Investigators. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. Eur Heart J 2015;36:288-296.
4. Al-Khatib SM, Thomas L, Wallentin L, Lopes RD, Gersh B, Garcia D, Ezekowitz J, Alings M, Yang H, Alexander JH, Flaker G, Hanna M, Granger CB. Outcomes of apixaban vs warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J 2013;34:2464-2471.
5. Flaker G, Ezekowitz M, Yusuf S, Wallentin L, Noack H, Brueckmann M, Reilly P, Hohnloser SH, Connolly S. Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (randomized evaluation of long-term anticoagulation therapy) study. J Am Coll Cardiol 2012;59:854-855.
6. Disertori M, Franzosi MG, Barlera S, Cosmi F, Quintarelli S, Favereo C, Cappellini G, Fabbri G, Maggioni AP, Staszewsky L, Moroni LA, Latini R, GISSI-AF Investigators. Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: data from the GISSI-AF trial. BMC Cardiovascul Disord 2013;13:28.
7. Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilkler CM, Clayton QD, Ziegler PD. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: The TRENDS study. Circ Arrhythm Electrophysiol 2009;2:474-480.
8. Shanmugam N, Boerdlein A, Proff J, Ong P, Valencia O, Maier SK, Bauer WR, Paul V, Sack S. Detection of atrial high-rate events by continuous home monitoring: clinical significance in the heart failure-cardiac resynchronization therapy population. Europace 2011;14:230-237.
9. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH, ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012;366:120-29.
10. Botto G, Padeletti L, Santini M, Capucci A, Gulizia M, Zolezzi F, Favale S, Molon G, Ricci R, Bifi M, Russo G, Vimercati M, Corbucci G, Boriani G. Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. J Cardiovasc Electrophysiol 2009;20:241-248.
11. Lim HS, Willoughby SR, Schultz C, Alasady M, Rangnekar G, Dang J, Gan C, Lau DH, Roberts KC, Young GD, Worthley MI, Sanders P. Thrombogenic risk in patients with atrial fibrillation. J Am Coll Cardiol Clin Electrophysiol 2015;1:210-217.